Cervical cancer: a tale from HPV infection to PARP inhibitors

Minakshi Mann; Vikram Pratap Singh; Lalit Kumar

doi:10.1016/j.gendis.2022.09.014

您当前的位置：

首页 >

文章列表页 >

Cervical cancer: a tale from HPV infection to PARP inhibitors

Review article | 更新时间：2023-08-29

- Cervical cancer: a tale from HPV infection to PARP inhibitors
- Cervical cancer: a tale from HPV infection to PARP inhibitors
- Genes & Diseases 2023年10卷第4期
- 作者机构：
  
  1. Epigenetics Section, Mouse Cancer Genetics Program, Center for Cancer Research, National Cancer Institute, Frederick,MD,USA,21702
  2. Department of Oncoanaesthesia and Palliative Medicine, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences,New Delhi,India,110029
  3. Department of Medical Oncology, Dr. B.R.A. Institute Rotary Cancer Hospital, All India Institute of Medical Sciences,New Delhi,India,110029
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2022.09.014
  中图分类号：
- 纸质出版日期：2023，
  
  网络出版日期：2023-7-1，
扫描看全文
Minakshi Mann, Vikram Pratap Singh, Lalit Kumar. Cervical cancer: a tale from HPV infection to PARP inhibitors[J]. Genes & Diseases, 2023,10(4).

Minakshi Mann, Vikram Pratap Singh, Lalit Kumar. Cervical cancer: a tale from HPV infection to PARP inhibitors[J]. Genes & Diseases, 2023,10(4).
Minakshi Mann, Vikram Pratap Singh, Lalit Kumar. Cervical cancer: a tale from HPV infection to PARP inhibitors[J]. Genes & Diseases, 2023,10(4). DOI： 10.1016/j.gendis.2022.09.014.

Minakshi Mann, Vikram Pratap Singh, Lalit Kumar. Cervical cancer: a tale from HPV infection to PARP inhibitors[J]. Genes & Diseases, 2023,10(4). DOI： 10.1016/j.gendis.2022.09.014.

摘要

Abstract

Globally

cervical cancer (CxCa) ranks 4th common cancer among females and led to 569

847 incidences and 311

365 deaths in 2018. 80% of CxCa cases occur due to persistent infection with a high-risk subtype of human papillomavirus (HPV-16 and 18). Smoking

high parity

and co-infection with type 2 herpes simplex or HIV are other known risk factors for CxCa. Major histological subtypes are squamous (70%) and adenocarcinoma (25%). Presently

concurrent radiation plus cisplatin (CDDP)-based chemotherapy is the standard treatment for CxCa patients. However

CDDP resistance and toxic side effects limit its efficacy

leading to a poorer response rate and an expected overall survival ranging from 10 to 17.5 months. Reduced drug uptake

increased DNA damage repair

increased CDDP inactivation

and overexpressed Bcl-2 or caspase inhibition

are primarily accountable mechanisms for CDDP resistance and improving CDDP’s efficacy remains the major challenge. Poly (ADP-ribosyl) polymerase-1

an effective mediator of nucleotide excision repair pathway

is involved in DNA repair as well as maintaining genomic stability and is significantly expressed in malignant lymphomas

hepatocellular-

cervical- and colorectal carcinoma

which has been approved effective in maintenance therapy and may serve as an effective target to enhance CDDP sensitivity in CxCa. Here

we summarize the etiology and epidemiology of and treatment for CxCa

the mechanism responsible for chemotherapy resistance

PARP inhibitor as a possible therapy for CxCa

and other possible chemotherapeutic options for CxCa treatment.

关键词

Keywords

Cervical cancerChemotherapyCisplatinDisease etiology and histologyPARP inhibitorsResistance

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

Drug repurposing: A novel strategy to target cancer stem cells and therapeutic resistance

Ribonucleotide reductase M2 (RRM2): Regulation, function and targeting strategy in human cancer

Niclosamide (NA) overcomes cisplatin resistance in human ovarian cancer

Decrypting a path based approach for identifying the interplay between PI3K and GSK3 signaling cascade from the perspective of cancer